S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
All the trading advice you’ve ever received boils down to this (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
All the trading advice you’ve ever received boils down to this (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
All the trading advice you’ve ever received boils down to this (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
All the trading advice you’ve ever received boils down to this (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
All the trading advice you’ve ever received boils down to this (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
All the trading advice you’ve ever received boils down to this (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
All the trading advice you’ve ever received boils down to this (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
All the trading advice you’ve ever received boils down to this (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
All the trading advice you’ve ever received boils down to this (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
All the trading advice you’ve ever received boils down to this (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
All the trading advice you’ve ever received boils down to this (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
All the trading advice you’ve ever received boils down to this (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver

Eagle Pharmaceuticals Stock Price, News & Analysis (NASDAQ:EGRX)

$5.95
+0.10 (+1.71%)
(As of 12/1/2023 ET)
Compare
Today's Range
$5.62
$6.05
50-Day Range
$5.68
$15.77
52-Week Range
$5.53
$35.93
Volume
323,828 shs
Average Volume
219,535 shs
Market Capitalization
$77.29 million
P/E Ratio
5.04
Dividend Yield
N/A
Price Target
$17.00

Eagle Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Sell
1.00 Rating Score
Upside/​Downside
185.7% Upside
$17.00 Price Target
Short Interest
Bearish
5.24% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.29
Upright™ Environmental Score
News Sentiment
0.07mentions of Eagle Pharmaceuticals in the last 14 days
Based on 13 Articles This Week
Insider Trading
Selling Shares
$295,836 Sold Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.36 out of 5 stars

Medical Sector

255th out of 951 stocks

Pharmaceutical Preparations Industry

105th out of 439 stocks


EGRX stock logo

About Eagle Pharmaceuticals Stock (NASDAQ:EGRX)

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

EGRX Stock Price History

EGRX Stock News Headlines

New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Here's what Wall Street expects from Eagle Pharmaceuticals's earnings
Eagle Pharmaceuticals Announces Management Change
Eagle Pharmaceuticals's Earnings: A Preview
Eagle Pharmaceuticals Inc EGRX
Eagle Flies on Patent News
A Bird's Eye View Of Eagle Pharma
See More Headlines
Receive EGRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eagle Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2021
Today
12/02/2023
Next Earnings (Estimated)
12/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EGRX
Fax
N/A
Employees
134
Year Founded
2007

Price Target and Rating

Average Stock Price Target
$17.00
High Stock Price Target
$17.00
Low Stock Price Target
$17.00
Potential Upside/Downside
+185.7%
Consensus Rating
Sell
Rating Score (0-4)
1.00
Research Coverage
1 Analysts

Profitability

Net Income
$35.64 million
Pretax Margin
11.33%

Debt

Sales & Book Value

Annual Sales
$316.61 million
Cash Flow
$3.86 per share
Book Value
$17.94 per share

Miscellaneous

Free Float
9,234,000
Market Cap
$77.29 million
Optionable
Optionable
Beta
0.56

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Scott L. Tarriff (Age 63)
    Founder, President, CEO & Director
    Comp: $1.51M
  • Mr. Brian Joseph Cahill (Age 54)
    Chief Financial Officer
    Comp: $606.06k
  • Mr. Ryan Debski
    Executive VP, General Counsel & Chief Compliance Officer
  • Mr. Daniel O'Connor (Age 43)
    Executive VP, Chief Strategy Officer & Head of Corporate Development
  • Dr. Valentin R. Curt M.D.
    Senior Vice President of Clinical Drug Development
  • Dr. Gaozhong Zhu Ph.D.
    Senior Vice President of Pharmaceutical Development
  • Ms. Debra M. Hussain
    Senior VP & Head of Commercial
  • Mr. Reed McClung
    Executive Vice President of Oncology Business Development














EGRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Eagle Pharmaceuticals stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eagle Pharmaceuticals in the last twelve months. There are currently 1 sell rating for the stock. The consensus among Wall Street analysts is that investors should "sell" EGRX shares.
View EGRX analyst ratings
or view top-rated stocks.

What is Eagle Pharmaceuticals' stock price target for 2024?

1 brokerages have issued 12 month price objectives for Eagle Pharmaceuticals' shares. Their EGRX share price targets range from $17.00 to $17.00. On average, they predict the company's share price to reach $17.00 in the next year. This suggests a possible upside of 185.7% from the stock's current price.
View analysts price targets for EGRX
or view top-rated stocks among Wall Street analysts.

How have EGRX shares performed in 2023?

Eagle Pharmaceuticals' stock was trading at $29.23 at the start of the year. Since then, EGRX shares have decreased by 79.6% and is now trading at $5.95.
View the best growth stocks for 2023 here
.

When is Eagle Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, December 4th 2023.
View our EGRX earnings forecast
.

How were Eagle Pharmaceuticals' earnings last quarter?

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) released its quarterly earnings results on Tuesday, November, 9th. The specialty pharmaceutical company reported $0.56 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.44) by $1.00. The specialty pharmaceutical company earned $39.85 million during the quarter, compared to the consensus estimate of $46.70 million. Eagle Pharmaceuticals had a trailing twelve-month return on equity of 6.48% and a net margin of 6.04%. During the same quarter in the previous year, the business earned $0.51 earnings per share.

What guidance has Eagle Pharmaceuticals issued on next quarter's earnings?

Eagle Pharmaceuticals issued an update on its FY 2023 earnings guidance on Friday, October, 6th. The company provided earnings per share (EPS) guidance of $4.40-$4.70 for the period, compared to the consensus estimate of $4.58. The company issued revenue guidance of -.

What other stocks do shareholders of Eagle Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eagle Pharmaceuticals investors own include Gilead Sciences (GILD), Exelixis (EXEL), Teekay Tankers (TNK), AbbVie (ABBV), Intercept Pharmaceuticals (ICPT), Schnitzer Steel Industries (RDUS), bluebird bio (BLUE), Clovis Oncology (CLVS), GW Pharmaceuticals (GWPH) and Incyte (INCY).

Who are Eagle Pharmaceuticals' major shareholders?

Eagle Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Brandes Investment Partners LP (8.73%), Adage Capital Partners GP L.L.C. (3.85%), AQR Capital Management LLC (2.18%), Smith Graham & Co. Investment Advisors LP (2.10%), Ameriprise Financial Inc. (1.98%) and Acadian Asset Management LLC (1.82%). Insiders that own company stock include Richard A Edlin and Scott Tarriff.
View institutional ownership trends
.

How do I buy shares of Eagle Pharmaceuticals?

Shares of EGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:EGRX) was last updated on 12/2/2023 by MarketBeat.com Staff

My Account -